Feature Combination immunotherapy: the emerging treatment that removes cancer’s “cloak of invisibility”

Last year’s Nobel prize in physiology or medicine went to James P Allison and Tasuku Honjo for their work on cancer immunotherapy. Some doctors think that the emerging use of these treatments in combination, and with other treatments such as chemotherapy and radiotherapy, will lead to a step change in survival rates, particularly in cancers that are hard to treat.

Ten years ago patients with a diagnosis such as melanoma or lung cancer, which don’t respond well to traditional methods such as chemotherapy and radiotherapy, received a grim prognosis. Immunotherapy has changed this for some patients. For example, a randomised trial of 272 patients with advanced, previously treated squamous cell non-small cell lung cancer (NSCLC) found that the immunotherapy nivolumab (Opdivo, Bristol-Myers Squibb) increased one year survival to 42%, compared with 24% with chemotherapy (docetaxel).1

Avacta Group Plc (LON:AVCT) principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The source of

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow to $15

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a safe and

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also tracks whether

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The drug aims